Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5541-5546

  Yuhas, Yael ^a,c   Berent, Eva ^a   Ashkenazi, Shai ^a,b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; NITRIC OXIDE; RANTES; RIFAMPICIN;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENSITOMETRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SCREENING; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; CELL LINE; CYTOKINES; EPITHELIAL CELLS; HEP G2 CELLS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; LIVER; NITRIC OXIDE; RIFAMPIN;

EID: 81555201929     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05149-11     Document Type: Article

References (35)

1. Bautista, A. P. 2002. Neutrophilic infiltration in alcoholic hepatitis. Alcohol 27:17-21. (Pubitemid 34626479)
2. Bérubé, J., C. Bourdon, Y. Yao, and S. Rousseau. 2009. Distinct intracellular signaling pathways control the synthesis of IL-8 and RANTES in TLR1/TLR2, TLR3 or NOD1 activated human airway epithelial cells. Cell Signalling 21:448-456.
3. Blanchard, J. S. 1998. The ying and yang of rifampicin. Nat. Med. 4:14-15. (Pubitemid 28133068)
4. Bogdan, C. 2001. Nitric oxide and the immune response. Nat. Immunol. 2:907-916. (Pubitemid 32976162)
5. Chen, T., R. Zamora, B. Zuckerbraun, and T. R. Billiar. 2003. Role of nitric oxide in liver injury. Curr. Mol. Med. 3:519-526. (Pubitemid 37168596)
6. Dong, W., et al. 1998. Cytokine expression in hepatocytes: role of oxidant stress. J. Interferon Cytokine Res. 18:629-638. (Pubitemid 28391591)
7. Gilchrist, M., and A. D. Befus. 2007. Interferon-γ regulates chemine expression and release in the human mast cell line HMC1: role of nitric oxide. Immunology 123:209-217.
8. Giustizieri, M. L., C. Albanesi, C. Scarponi, O. De Pita, and F. Girolomoni. 2002. Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am. J. Pathol. 161:1409-1418.
9. Harbrecht, B. G., and T. R. Billiar. 1995. The role of nitric oxide in Kupffer cell-hepatocyte interactions. Shock 3:79-87.
10. Herr, A. S., G. M. Wochnik, M. C. Rosenhagen, F. Holsboer, and T. Rein. 2000. Rifampicin is not an activator of glucocorticoid receptor. Mol. Pharmacol. 57:732-737. (Pubitemid 30183713)
11. Hoffmann, E., O. Dittrich-Breiholz, H. Holtmann, and M. Kracht. 2002. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72:847-855. (Pubitemid 35365158)
12. Jaffuel, D., et al. 1999. Rifampicin is not an activator of the glucocorticoid receptor in A549 human alveolar cells. Mol. Pharmacol. 55:841-846. (Pubitemid 29214603)
13. Kleinert, H., P. M. Schwarz, and U. U. Forstermann. 2003. Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 384:1343-1364. (Pubitemid 37508640)
14. Kwon, S., and S. C. George. 1999. Synergistic cytokine-induced nitric oxide production in human alveolar epithelial cells. Nitric Oxide 3:348-357. (Pubitemid 29406763)
15. Labro, M.-T. 2005. Anti-inflammatory activity of ansamycins. Expert Rev. Anti Infect. Ther. 3:91-103. (Pubitemid 40277841)
16. Li, J., and T. R. Billiar. 1999. Nitric oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am. J. Physiol. 276:G1069-G1073. (Pubitemid 29251903)
17. Ma, P., et al. 2004. Nitric oxide post-transcriptionally up-regulates LPS-induced IL-8 expression through p38 MAPK activation. J. Leukoc. Biol. 76:278-287. (Pubitemid 38857197)
18. MacMicking, J. D., et al. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 94:5243-5248.
19. Majano, P. L., et al. 2004. N-acetyl-cysteine modulates inducible nitric oxide syntase gene expression in human hepatocytes. J. Hepatol. 40:632-637. (Pubitemid 38367785)
20. Marion, R., et al. 2005. L-arginine modulates CXC chemokines in the human intestinal epithelial cell line HCT-98 by the NO pathway. Biochimie 87:1048-1055. (Pubitemid 41572634)
21. Mlambo G, and L. B. Sigola. 2003. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effect on nitrite and TNF-α production. Int. Immunopharmacol. 3:513-522. (Pubitemid 36419512)
22. Mühl, H., et al. 2000. Nitric oxide augments release of chemokines from monocytic U937 cells: modulation by anti-inflammatory pathways. Free Radic. Biol. Med. 29:969-980.
23. Neuman, M. G., et al. 1999. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytotoxicity. Clin. Biochem. 32:519-536. (Pubitemid 30007763)
24. O'Kane, C. M., J. J. Boyle, D. E. Horncastle, P. T. Elkington, and J. S. Friedland. 2007. Monocyte-dependent fibroblast CXCL8 secretion occurs in tuberculosis and limits survival of mycobacteria within macrophages. J. Immunol. 178:3767-3776. (Pubitemid 46417645)
25. Pahlevan, A. A., D. J. Wright, L. Bradley, C. Smith, and B. M. Foxwell. 2002. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J. Antimicrob. Chemother. 49:531-534. (Pubitemid 34223675)
26. Saad, E. I., S. M. El-Gowilly, M. O. Sherhaa, and A. E. Bistawroos. 2010. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food Chem. Toxicol. 48:1869-1875.
27. Tentori, L., et al. 1998. Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrob. Agents Chemother. 42:550-554. (Pubitemid 28114807)
28. Toell, A., K.-D. Kroncke, H. Kleinert, and C. Carlberg. 2002. Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands. J. Cell Biochem. 85:72-82. (Pubitemid 34204070)
29. Tostmann, A., et al. 2008. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 23:192-202. (Pubitemid 351257678)
30. Yasuda, K., et al. 2008. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab. Dispos. 36:1689-1697.
31. Yuhas, Y., E. Berent, H. Ovadia, I. Azoulay, and S. Ashkenazi. 2006. Rifampin augments cytokine-induced nitric oxide production in human alveolar epithelial cells. Antimicrob. Agents Chemother. 50:396-398. (Pubitemid 43042957)
32. Yuhas, Y., I. Azoulay-Alfaguter, E. Berent, and S. Ashkenazi. 2007. Rifampin inhibits prostaglandin E2 production and arachidonic acid release in human alveolar epithelial cells. Antimicrob. Agents Chemother. 51:4225-4230. (Pubitemid 350209869)
33. Yuhas, Y., E. Berent, R. Cohen, and S. Ashkenazi. 2009. Roles of NF-κB activation and peroxisome proliferator-activated receptor gamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells. Antimicrob. Agents Chemother. 53:1539-1545.
34. Ziglam, H. M., D. R. Baldwin, I. Daniels, J. M. Andrews, and R. G. Finch. 2002. Rifampin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 50:1011-1015. (Pubitemid 36032825)
35. Ziglam, H. M., I. Daniels, and R. G. Finch. 2004. Immunomodulating activity of rifampicin. J. Chemother. 16:357-361. (Pubitemid 39049886)